ArticleCell death & disease2026
Mitochondrial AK3 inhibits nuclear β-catenin localization and its activation through enhancing mitochondrial activity.
Article in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Hypothalamic Inflammaging: A Central Driver of Type 2 Diabetes Mellitus and Metabolic Disease in Aging.Diabetes & metabolism journal · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The aberrant Wnt/β-catenin signaling is tightly associated with developmental disorders and tumorigenesis. However, spatial regulation of cytoplasmic β-catenin with regard to its nuclear accumulation and signaling activation remains poorly understood. Herein, we show that mitochondrial adenylate kinase 3 (AK3), which is involved in the TCA cycle, regulates nuclear β-catenin localization and its activation. Transcriptome profiling across multiple cancer patient datasets revealed that AK3 and oxidative phosphorylation pathway are highly correlated with Wnt/β-catenin signaling and prognosis of patients. Using cancer cell lines, we found that AK3 enzymatic activity inhibited β-catenin signaling and cell proliferation by attenuating nuclear β-catenin accumulation. Intriguingly, mitofusins (MFN1 & 2) were identified as β-catenin interactors and demanded for the AK3-mediated β-catenin signaling regulation. Additionally, β-catenin-mitofusins interactions were enhanced by AK3 expression but disrupted by treatment with CCCP. These results suggest that metabolically active mitochondria induced by AK3 restrain β-catenin signaling through modulating the β-catenin-mitofusins interactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.